

# George Pentheroudakis

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5569605/publications.pdf>

Version: 2024-02-01

43  
papers

1,046  
citations

567281

15  
h-index

434195

31  
g-index

45  
all docs

45  
docs citations

45  
times ranked

2028  
citing authors

#	ARTICLE	IF	CITATIONS
1	Establishment of CORONET, COVID-19 Risk in Oncology Evaluation Tool, to Identify Patients With Cancer at Low Versus High Risk of Severe Complications of COVID-19 Disease On Presentation to Hospital. JCO Clinical Cancer Informatics, 2022, , .	2.1	7
2	Genotype-phenotype associations in colorectal adenocarcinomas and their matched metastases. Human Pathology, 2021, 107, 104-116.	2.0	6
3	Genotyping data of routinely processed matched primary/metastatic tumor samples. Data in Brief, 2021, 34, 106646.	1.0	2
4	Androgen Receptor and <i>PIM1</i> Expression in Tumor Tissue of Patients With Triple-negative Breast Cancer. Cancer Genomics and Proteomics, 2021, 18, 147-156.	2.0	4
5	A Challenging Task: Identifying Patients with Cancer of Unknown Primary (CUP) According to ESMO Guidelines: The CUPISCO Trial Experience. Oncologist, 2021, 26, e769-e779.	3.7	48
6	AGAPP: efficacy of first-line cisplatin, 5-fluorouracil with afatinib in inoperable gastric and gastroesophageal junction carcinomas. A Hellenic Cooperative Oncology Group study. Acta Oncologica, 2021, 60, 785-793.	1.8	5
7	mRNA expression of specific HER ligands and their association with clinical outcome in patients with metastatic breast cancer treated with trastuzumab. Oncology Letters, 2021, 23, 23.	1.8	1
8	Clinical Significance of Major Angiogenesis-Related Effectors in Patients with Metastatic Breast Cancer Treated with Trastuzumab-based Regimens. Cancer Research and Treatment, 2021, , .	3.0	1
9	ESMO management and treatment adapted recommendations in the COVID-19 era: colorectal cancer. ESMO Open, 2020, 5, e000826.	4.5	60
10	ESMO Management and treatment adapted recommendations in the COVID-19 era: Pancreatic Cancer. ESMO Open, 2020, 5, e000804.	4.5	61
11	Old drug, new clinical use, no manâ€™s land for the indication: an awareness call from European experts. ESMO Open, 2020, 5, e000615.	4.5	10
12	First Line Gemcitabine/Pazopanib in Locally Advanced and/or Metastatic Biliary Tract Carcinoma. A Hellenic Cooperative Oncology Group Phase II Study. Anticancer Research, 2020, 40, 929-938.	1.1	7
13	Efficacy and Safety of First-Line Everolimus Therapy Alone or in Combination with Octreotide in Gastroenteropancreatic Neuroendocrine Tumors. A Hellenic Cooperative Oncology Group (HeCOG) Study. Biology, 2020, 9, 51.	2.8	2
14	Tumor Mutational Patterns and Infiltrating Lymphocyte Density in Young and Elderly Patients With Breast Cancer. Cancer Genomics and Proteomics, 2020, 17, 181-193.	2.0	2
15	A case report of psoriasis flare following immunotherapy: Report of an important entity and literature review. SAGE Open Medical Case Reports, 2020, 8, 2050313X1989770.	0.3	12
16	Acquired Hemophilia in an Elderly Patient with Carcinoma of the Ampulla of Vater. Case Reports in Oncology, 2020, 13, 1-6.	0.7	4
17	Prognostic impact of stromal and intratumoral CD3, CD8 and FOXP3 in adjuvantly treated breast cancer: do they add information over stromal tumor-infiltrating lymphocyte density?. Cancer Immunology, Immunotherapy, 2020, 69, 1549-1564.	4.2	19
18	Angiogenic and Antiangiogenic VEGFA Splice Variants in Colorectal Cancer: Prospective Retrospective Cohort Study in Patients Treated With Irinotecan-Based Chemotherapy and Bevacizumab. Clinical Colorectal Cancer, 2019, 18, e370-e384.	2.3	18

#	ARTICLE	IF	CITATIONS
19	Cyclin D1 differential activation and its prognostic impact in patients with advanced breast cancer treated with trastuzumab. <i>ESMO Open</i> , 2019, 4, e000441.	4.5	3
20	How I treat cancers of unknown primary. <i>ESMO Open</i> , 2019, 4, e000502.	4.5	6
21	Genetic mapping of pancreatic cancer by targeted next-generation sequencing in a cohort of patients managed with nab-paclitaxel-based chemotherapy or agents targeting the EGFR axis: a retrospective analysis of the Hellenic Cooperative Oncology Group (HeCOG). <i>ESMO Open</i> , 2019, 4, e000525.	4.5	8
22	Mismatch repair deficiency/microsatellite instability testing as predictive immunotherapy biomarkers—possible diagnostic missteps trusting a single method. <i>Annals of Translational Medicine</i> , 2019, 7, S329-S329.	1.7	1
23	Prognostic implications of mismatch repair deficiency in patients with nonmetastatic colorectal and endometrial cancer. <i>ESMO Open</i> , 2019, 4, e000474.	4.5	34
24	Molecular findings reveal possible resistance mechanisms in a patient with ALK-rearranged lung cancer: a case report and literature review. <i>ESMO Open</i> , 2019, 4, e000561.	4.5	4
25	Characterization and prevalence of two novel CHEK2 large deletions in Greek breast cancer patients. <i>Journal of Human Genetics</i> , 2018, 63, 877-886.	2.3	7
26	AMALTHEA: Prospective, Single-Arm Study of the Hellenic Cooperative Oncology Group (HeCOG) Evaluating Efficacy and Safety of First-Line FOLFIRI+ Aflibercept for 6 Months Followed by Aflibercept Maintenance in Patients With Metastatic Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2018, 17, e631-e637.	2.3	12
27	Postoperative chemotherapy with single-agent fluoropyrimidines after resection of colorectal cancer liver metastases: a meta-analysis of randomised trials. <i>ESMO Open</i> , 2018, 3, e000343.	4.5	11
28	TAILORing targeted therapies to the right patient at the right time: how close are we?. <i>Annals of Translational Medicine</i> , 2018, 6, S87-S87.	1.7	0
29	Nivolumab-induced hypothyroidism and selective pituitary insufficiency in a patient with lung adenocarcinoma: a case report and review of the literature. <i>ESMO Open</i> , 2017, 2, e000217.	4.5	20
30	Current and future biomarkers in colorectal cancer. <i>Annals of Gastroenterology</i> , 2017, 30, 613-621.	0.6	88
31	Primary Pulmonary Malignant Melanoma: Report of an Important Entity and Literature Review. <i>Case Reports in Oncological Medicine</i> , 2017, 2017, 1-9.	0.3	22
32	Pancreatic resection for renal cell carcinoma metastasis: An exceptionally rare coexistence. <i>International Journal of Surgery Case Reports</i> , 2016, 27, 198-201.	0.6	15
33	Cancer of unknown primary: time to put the pieces of the puzzle together?. <i>Lancet Oncology</i> , The, 2016, 17, 1339-1340.	10.7	4
34	Management of patients with recurrent/advanced cervical cancer beyond first line platinum regimens: Where do we stand? A literature review. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 108, 164-174.	4.4	134
35	Update on clinical research and state of the art management of patients with advanced sarcomas and GIST. <i>ESMO Open</i> , 2016, 1, e000065.	4.5	4
36	Non-epithelial Ovarian Cancer: Elucidating Uncommon Gynaecological Malignancies. <i>Anticancer Research</i> , 2016, 36, 5031-5042.	1.1	47

#	ARTICLE	IF	CITATIONS
37	Prognostic significance of <scp>WNT</scp> and hedgehog pathway activation markers in cancer of unknown primary. <i>European Journal of Clinical Investigation</i> , 2015, 45, 1145-1152.	3.4	4
38	Cancer of Unknown Primary origin in the genomic era: Elucidating the dark box of cancer. <i>Cancer Treatment Reviews</i> , 2015, 41, 598-604.	7.7	46
39	Predictive biomarkers to chemotherapy in patients with advanced melanoma receiving the combination of cisplatin–vinblastine–temozolomide (PVT) as first-line treatment: a study of the Hellenic Cooperative Oncology Group (HECOG). <i>Anticancer Research</i> , 2015, 35, 1105-13.	1.1	8
40	Relapsing Episodes of Loss of Consciousness in a Patient With Hepatocellular Carcinoma. <i>World Journal of Oncology</i> , 2014, 5, 214-219.	1.5	4
41	Novel microRNA-based assay demonstrates 92% agreement with diagnosis based on clinicopathologic and management data in a cohort of patients with carcinoma of unknown primary. <i>Molecular Cancer</i> , 2013, 12, 57.	19.2	43
42	Global microRNA profiling in favorable prognosis subgroups of cancer of unknown primary (CUP) demonstrates no significant expression differences with metastases of matched known primary tumors. <i>Clinical and Experimental Metastasis</i> , 2013, 30, 431-439.	3.3	23
43	Cancer and pregnancy: Poena magna, not anymore. <i>European Journal of Cancer</i> , 2006, 42, 126-140.	2.8	229